Complete GLP-1 Medication List: Every Option in 2026
Prices verified May 22, 2026 · Updated for 2026
The GLP-1 landscape in 2026 includes 7 FDA-approved medications across injectable and oral formats, plus several promising pipeline drugs. Semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) dominate the market, but Foundayo (orforglipron), CagriSema, and retatrutide are reshaping what's possible.
The current landscape
The GLP-1 medication class has expanded dramatically since the first approval (exenatide/Byetta) in 2005. As of May 2026, patients have more options than ever—and several pipeline drugs promise even stronger results. This is the complete reference guide.
FDA-approved GLP-1 medications for weight loss
| Medication | Active ingredient | Format | Avg. weight loss | Cash-pay price |
|---|---|---|---|---|
| Wegovy (injection) | Semaglutide 2.4mg | Weekly injection | 14.9% | $349/mo (NovoCare) |
| Wegovy (pill) | Semaglutide 25mg | Daily pill | 13.6% | $149–$299/mo |
| Zepbound | Tirzepatide 15mg | Weekly injection | 20.9% | $299–$699/mo (LillyDirect) |
| Foundayo | Orforglipron 17.2mg | Daily pill | ~11% | $149/mo (LillyDirect) |
| Saxenda | Liraglutide 3.0mg | Daily injection | ~8% | $1,349/mo list |
FDA-approved for diabetes (commonly used off-label for weight)
| Medication | Active ingredient | Format | Primary indication |
|---|---|---|---|
| Ozempic | Semaglutide (up to 2.0mg) | Weekly injection | Type 2 diabetes + CV risk |
| Mounjaro | Tirzepatide (up to 15mg) | Weekly injection | Type 2 diabetes |
| Rybelsus | Oral semaglutide (14mg) | Daily pill | Type 2 diabetes |
| Trulicity | Dulaglutide | Weekly injection | Type 2 diabetes + CV risk |
| Victoza | Liraglutide 1.8mg | Daily injection | Type 2 diabetes |
Older/legacy GLP-1 medications
These are still FDA-approved but rarely prescribed for new patients due to inferior efficacy compared to newer options:
- Byetta (exenatide) — twice-daily injection, the original GLP-1 (2005)
- Bydureon (exenatide extended-release) — weekly injection, some formulations discontinued
- Adlyxin (lixisenatide) — daily injection, less commonly prescribed
- Tanzeum (albiglutide) — withdrawn from market in 2018 for commercial reasons
The pipeline: what's coming next
| Drug | Mechanism | Weight loss (trials) | Status (May 2026) |
|---|---|---|---|
| CagriSema | Semaglutide + cagrilintide (amylin analog) | 22.7% (REDEFINE 1) | FDA decision expected 2026 |
| Wegovy HD 7.2mg | Higher-dose semaglutide | ~19% (Phase 3) | Filed for FDA approval |
| Retatrutide | Triple GLP-1/GIP/glucagon agonist | 24.2% (Phase 2, 48 wks) | Phase 3 ongoing |
| Survodutide | Dual GLP-1/glucagon agonist | ~19% (Phase 2) | Phase 3 ongoing, MASH focus |
| Pemvidutide | Dual GLP-1/glucagon agonist | ~15% (Phase 2) | Phase 2/3 ongoing |
CagriSema (Novo Nordisk) is the nearest-term addition, potentially approved in 2026. At 22.7% weight loss, it would match or exceed Zepbound. Retatrutide (Eli Lilly) is the most exciting pipeline drug—the triple-agonist mechanism produced 24.2% weight loss in Phase 2, the highest ever recorded in a clinical trial. Phase 3 results are expected in 2026–2027.
Compounded options
Compounded versions of semaglutide and tirzepatide are widely available through telehealth providers at $99–$399/mo. These use the same active pharmaceutical ingredients but are mixed by compounding pharmacies, not manufactured by Novo Nordisk or Eli Lilly. Compounded medications are not FDA-approved.
The FDA has been increasing enforcement actions against compounding pharmacies in 2026, with 30+ warning letters issued to telehealth companies. Patients using compounded GLP-1s should verify their provider's pharmacy credentials (503A/503B licensing, LegitScript verification).
How to read this landscape
For most patients in May 2026, the practical choice comes down to four options: compounded semaglutide (cheapest injectable), Wegovy pill or Foundayo (cheapest oral), Wegovy injection (most data), or Zepbound (most weight loss). Everything else is either legacy, off-label, or not yet approved. The pipeline drugs—especially CagriSema and retatrutide—will expand this list by 2027.
🏥 Compare Current GLP-1 Providers
Compounded medications are not FDA-approved. Consult a licensed provider to determine if treatment is appropriate for you.
Embody
Compounded semaglutide with metabolic report, 1:1 guidance, and personalized plan.
Start for $149GobyMeds
LegitScript-verified. Semaglutide & tirzepatide bundles, free consult, free shipping.
Get StartedSesame Care
Access to FDA-approved brand-name GLP-1 medications through licensed providers.
Get StartedOak Weight Loss
Compounded semaglutide and tirzepatide at a single flat rate regardless of dose.
See PlansRelated Verdicts
Semaglutide vs. Tirzepatide: The 2026 Verdict →Injectable vs. Oral GLP-1: Which Format Wins? →Sources & References
- FDA: Approved GLP-1 receptor agonist medications. Updated 2026.
- Novo Nordisk: REDEFINE 1 trial (CagriSema). 2025.
- Jastreboff AM, et al. Retatrutide Phase 2 results. NEJM. 2023.
- Eli Lilly: Foundayo (orforglipron) FDA approval, April 2026.
- FDA Warning Letters to compounding pharmacies, 2025–2026.
- Provider pricing verified May 2026.